Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
15.44
+1.27 (8.96%)
At close: Jul 17, 2026, 4:00 PM EDT
15.88
+0.44 (2.85%)
After-hours: Jul 17, 2026, 7:59 PM EDT
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$2,363,785
Market Cap
2.32B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Nurix Therapeutics | 317 |
| Mesoblast | 81 |
| Mineralys Therapeutics | 76 |
| Nektar Therapeutics | 63 |
| Sionna Therapeutics | 59 |
BHVN News
- 10 days ago - Biohaven’s Bruce Car retires as chief scientific officer - TheFly
- 10 days ago - Biohaven Announces Scientific Leadership Transitions - PRNewsWire
- 19 days ago - Biohaven announces completion of enrollment in RISE3 trial - TheFly
- 19 days ago - Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator - PRNewsWire
- 20 days ago - Biohaven falls -9.8% - TheFly
- 20 days ago - Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease - TheFly
- 20 days ago - Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - PRNewsWire
- 20 days ago - Biohaven downgraded to Underperform from Neutral at BofA - TheFly